Molecular Partners (NASDAQ:MOLN – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Molecular Partners to related companies based on the strength of its analyst recommendations, dividends, valuation, profitability, earnings, risk and institutional ownership.
Volatility and Risk
Molecular Partners has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Molecular Partners’ peers have a beta of -1.84, indicating that their average stock price is 284% less volatile than the S&P 500.
Valuation and Earnings
This table compares Molecular Partners and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Molecular Partners | $5.65 million | -$74.41 million | -1.69 |
| Molecular Partners Competitors | $688.59 million | $7.69 million | -18.81 |
Molecular Partners’ peers have higher revenue and earnings than Molecular Partners. Molecular Partners is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Molecular Partners and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Molecular Partners | N/A | -80.03% | -62.56% |
| Molecular Partners Competitors | -12,224.09% | -202.33% | -31.23% |
Analyst Ratings
This is a summary of current recommendations for Molecular Partners and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Molecular Partners | 1 | 1 | 2 | 0 | 2.25 |
| Molecular Partners Competitors | 9916 | 15312 | 45656 | 1602 | 2.54 |
Molecular Partners presently has a consensus price target of $8.38, indicating a potential upside of 194.17%. As a group, “Biotechnology” companies have a potential upside of 126.24%. Given Molecular Partners’ higher possible upside, equities analysts plainly believe Molecular Partners is more favorable than its peers.
Insider & Institutional Ownership
26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 5.9% of Molecular Partners shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Molecular Partners peers beat Molecular Partners on 8 of the 12 factors compared.
About Molecular Partners
Molecular Partners is a Swiss biotechnology company that develops protein-based medicines using its proprietary DARPin platform. Designed ankyrin repeat proteins, or DARPins, are engineered to bind specific biological targets and can be developed to act on one or several targets. The company’s research focuses on therapeutic candidates for cancer and other serious diseases. Its pipeline has included treatments designed to engage immune cells against tumors and to target proteins found in the tumor environment.
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
